Thomas M, Tri V H, Perrault M
Sem Hop. 1977;53(34-35):1857-62.
24 diabetics, (9 thin diabetics, 14 cases of maturity onset diabetes, 6 intermediate forms and one case of partial pancreatectomy) received 7.5 to 20 mg of bromocriptine (CB 154) per 24 hours. A definite improvement in glucose metabolism was noted in 6 cases, a definite aggravation in 4 cases; 14 results were not significant (p-0.05). The efficacy of CB 154 did not depend on the clinical type nor on the patient's age. It appeared related to duration of the diabetes (2 years and 3 months in improved patients, 11 years in aggravated patients) and perhaps the degree of retinopathy (more frequent and severe in aggravated patients). The improvement seems to be linked to the existence in certain diabetics of a paradoxical regulation of STH secretion as in acromegaly. The possibility of a peripheral effect of bromocriptine on insulin and glucagon is discussed. The CB 154 test (estimations of STH after a single dose of 2.5 mg) permits one to foresee the efficacy of the drug and perhaps the risk of diabetic retinopathy.
24名糖尿病患者(9名消瘦型糖尿病患者、14例成年型糖尿病患者、6例中间型及1例部分胰腺切除术后患者)每24小时接受7.5至20毫克溴隐亭(CB 154)治疗。6例患者的糖代谢有明显改善,4例明显恶化;14例结果无显著差异(p>0.05)。CB 154的疗效与临床类型及患者年龄无关。其似乎与糖尿病病程有关(病情改善患者的病程为2年3个月,病情恶化患者的病程为11年),可能还与视网膜病变程度有关(病情恶化患者中更常见且更严重)。这种改善似乎与某些糖尿病患者存在类似肢端肥大症中生长激素(STH)分泌的反常调节有关。文中讨论了溴隐亭对胰岛素和胰高血糖素的外周作用可能性。CB 154试验(单次服用2.5毫克后测定生长激素)可让人预见该药物的疗效以及糖尿病视网膜病变的风险。